MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-25-0100

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2025

Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.

Hernando-Calvo Alberto, Carvajal Richard D, Paik Paul K, Morris Van Karlyle, Zandberg Dan P, Kaczmar John M, Bohr David N, Reiners Ralf D, Gharakhani Elham, Salazar Rachel L, Lizotte Patrick Hall, Ivanova Elena V, Bedard Philippe L, Hanna Glenn J

СтатьяКлиническое исследование I фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: To evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of ficerafusp alfa (BCA101), a first-in-class bifunctional protein targeting EGFR and TGF-β, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.

PATIENTS AND

METHODS

At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64-1,500 mg) or in combination (240-1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks). The primary objective was to determine safety/tolerability. Secondary objectives included assessment of pharmacokinetics, immunogenicity, and preliminary efficacy per investigator-assessed response. Exploratory analyses included pharmacodynamic biomarkers.

RESULTS

Among 61 patients (monotherapy, n = 46; combination, n = 15), the most common treatment-related adverse events included acneiform dermatitis (46%) and fatigue (20%) with monotherapy and acneiform dermatitis (73%), fatigue (53%), pruritus (40%), epistaxis (40%), and maculopapular rash (40%) with combination therapy. One patient had a dose-limiting toxicity with 1,250-mg monotherapy (grade 3 anemia and hematuria). The MTD was not reached in either cohort. With monotherapy, objective response was observed in one of 42 evaluable patients and 16 (38%) achieved stable disease. With combination therapy, four of 13 evaluable patients (31%) had a confirmed response, including one with head and neck squamous cell carcinoma refractory to anti-PD-1 therapy and cetuximab. Prolonged neutralization of plasma TGF-β1 was observed at doses ≥500 mg.

CONCLUSIONS

Ficerafusp alfa exhibited a manageable safety profile and clinical activity as monotherapy and in combination with pembrolizumab, with exposure increasing proportionally at anticipated therapeutic doses. See related commentary by Choudhury et al., p. 4617.

Для цитирования: Hernando-Calvo Alberto, Carvajal Richard D, Paik Paul K, Morris Van Karlyle, Zandberg Dan P, Kaczmar John M, Bohr David N, Reiners Ralf D, Gharakhani Elham, Salazar Rachel L, Lizotte Patrick Hall, Ivanova Elena V, Bedard Philippe L, Hanna Glenn J. Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. DOI: 10.1158/1078-0432.ccr-25-0100.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.